<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795192</url>
  </required_header>
  <id_info>
    <org_study_id>SMARTT-002</org_study_id>
    <nct_id>NCT05795192</nct_id>
  </id_info>
  <brief_title>SB17170 Phase1 Trial in Healthy Volunteer</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, PK/PD, Food Effect, and Ethnicity Effect of SB17170 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SPARK Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SPARK Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to learn about the safety, tolerability, and pharmacokinetic&#xD;
      properties of SB17170 and its active metabolite SB1703 in single and multiple oral&#xD;
      administration in healthy adults.&#xD;
&#xD;
      The main questions it aims to answer are the safety, tolerability, and PK characteristics of&#xD;
      SB17170 in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial aims to learn about the safety, tolerability, and Pharmacokinetic&#xD;
      properties of SB17170 and its active metabolite SB1703 in single and multiple oral&#xD;
      administration in healthy adults.&#xD;
&#xD;
      The main questions it aims to answer are the safety, tolerability, and PK characteristics of&#xD;
      SB17170 in healthy adults.&#xD;
&#xD;
      The second questions are&#xD;
&#xD;
        -  To explore biomarkers and evaluate pharmacodynamic properties with ex-vivo test and&#xD;
           proteome assay for SB17170&#xD;
&#xD;
        -  To evaluate the effects of ethnic differences on the safety, tolerability, and&#xD;
           pharmacokinetic properties of SB17170 in healthy Korean and Caucasian adults.&#xD;
&#xD;
        -  To evaluate the effect of food between Fast and high-fat meals on safety, tolerability,&#xD;
           and pharmacokinetic properties of SB17170 in healthy adults.&#xD;
&#xD;
      The difference between SB17170 and placebo on safety, tolerability, and PK/PD properties will&#xD;
      be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 14, 2023</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Block randomized, double-blind design controlling with IWRS</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>From Day 1 to Day 7 for Single dose, From Day 1 to Day 9 for Multiple dose</time_frame>
    <description>Safety and Tolerability in healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Area Under the Curve from dosing to the time of the last measured concentration</measure>
    <time_frame>Baseline 0hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve from time 0 extrapolated to infinite time(AUCinf)</measure>
    <time_frame>Baseline 0hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum (or peak) serum concentration(Cmax)</measure>
    <time_frame>Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to reach Cmax(Tmax)</measure>
    <time_frame>Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Half life(t1/2) of SB17170 and active metabolite</measure>
    <time_frame>Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of oral clearance(CL/F)</measure>
    <time_frame>Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Renal clearance(CLR)</measure>
    <time_frame>Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The volume of distribution(vd/f)</measure>
    <time_frame>Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of unchanged drug to metabolite(Metabolic ratio)</measure>
    <time_frame>Baseline 0 hour, 20minute, 40minute, 1hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour, 24hour, 48hour</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentrations of HMGB1 between the active and placebo groups</measure>
    <time_frame>Baseline 0 hour, 1.5hour, 24hour,</time_frame>
    <description>High Mobility Group Box1(HMGB1) as a Pharmacodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentrations of Interferon-gamma between the active and placebo groups</measure>
    <time_frame>Baseline 0 hour, 1.5hour, 24hour,</time_frame>
    <description>Interferon-gamma( IFN-γ) as a Pharmacodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentrations of TNF-α between the active and placebo groups</measure>
    <time_frame>Baseline 0 hour, 1.5hour, 24hour,</time_frame>
    <description>Tumor Necrosis Factor-alpha human(TNF-α) as a Pharmacodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentratiosn of Interleukin-6 between the active and placebo groups</measure>
    <time_frame>Baseline 0 hour, 1.5hour, 24hour,</time_frame>
    <description>Interleukin-6 as a Pharmacodynamic parameter</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Safety Issues</condition>
  <condition>Tolerability</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>SB17170 of 50mg, Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 50mg capsule, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of 50mg, Single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 50mg, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB17170 of 150mg, Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 100mg and 50mg capsules, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of 150mg, Single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 100mg and 50mg capsules, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB17170 of 250mg, Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg capsule, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of 250mg, Single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg capsule, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB17170 of 500mg, Single dose, Food-effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 2 capsules, QD for 1 day(single).&#xD;
Food-effect test for the expected efficacy dose&#xD;
1st period without a meal&#xD;
Wash out period more than 7 days&#xD;
2nd period with a high-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of 500mg, Single dose, Food-effect</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 2 250mg 2 capsules, QD for 1 day(single).&#xD;
Food-effect test for the expected efficacy dose&#xD;
1st period without a meal&#xD;
Wash out period more than 7 days&#xD;
2nd period with a high-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB17170 of 1000mg, Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 4capsules, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of 1000mg, Single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 2 250mg 4 capsules, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB17170 of 1500mg, Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional dose Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg 6 capsules, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of 1500mg, Single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Optional dose Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg 6 capsules, QD for 1 day(single).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB17170 of 250mg, Multiple dose for 7days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 1 capsule, QD for 7 days(multiple).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of 250mg, Multiple dose for 7days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 1 capsule, QD for 7 days(multiple).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB17170 of 500mg, Multiple dose for 7days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 2 capsules, QD for 7 days(multiple).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of 500mg, Multiple dose for 7days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 2 capsules, QD for 7 days(multiple).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB17170 of 1000mg, Multiple dose for 7days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional dose Assign 6 subjects per cohort including Korean and Caucasian. Prescribe SB17170 250mg, 4 capsules, QD for 7 days(multiple).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of 1000mg, Multiple dose for 7days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Optional dose Assign 2 subjects per cohort including Korean and Caucasian. Prescribe Placebo 250mg, 4 capsules, QD for 7 days(multiple).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB17170</intervention_name>
    <description>Taking SB17170 orally once a day</description>
    <arm_group_label>SB17170 of 1000mg, Multiple dose for 7days</arm_group_label>
    <arm_group_label>SB17170 of 1000mg, Single dose</arm_group_label>
    <arm_group_label>SB17170 of 1500mg, Single dose</arm_group_label>
    <arm_group_label>SB17170 of 150mg, Single dose</arm_group_label>
    <arm_group_label>SB17170 of 250mg, Multiple dose for 7days</arm_group_label>
    <arm_group_label>SB17170 of 250mg, Single dose</arm_group_label>
    <arm_group_label>SB17170 of 500mg, Multiple dose for 7days</arm_group_label>
    <arm_group_label>SB17170 of 500mg, Single dose, Food-effect</arm_group_label>
    <arm_group_label>SB17170 of 50mg, Single dose</arm_group_label>
    <other_name>SB1703</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Taking Placebo orally once a day</description>
    <arm_group_label>Placebo of 1000mg, Multiple dose for 7days</arm_group_label>
    <arm_group_label>Placebo of 1000mg, Single dose</arm_group_label>
    <arm_group_label>Placebo of 1500mg, Single dose</arm_group_label>
    <arm_group_label>Placebo of 150mg, Single dose</arm_group_label>
    <arm_group_label>Placebo of 250mg, Multiple dose for 7days</arm_group_label>
    <arm_group_label>Placebo of 250mg, Single dose</arm_group_label>
    <arm_group_label>Placebo of 500mg, Multiple dose for 7days</arm_group_label>
    <arm_group_label>Placebo of 500mg, Single dose, Food-effect</arm_group_label>
    <arm_group_label>Placebo of 50mg, Single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Korean or Caucasian adults between the ages of 19 and 50 as of the date of&#xD;
             written consent&#xD;
&#xD;
          -  Subjects with a body weight of 55.0 kg or more at the time of screening and a body&#xD;
             mass index (BMI) of 18.0 kg/m2 or more and less than 30.0 kg/m2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical significant medical history&#xD;
&#xD;
          -  Gastrointestinal disease or past history&#xD;
&#xD;
          -  Hypersensitivity or clinically significant hypersensitivity to the components of&#xD;
             investigational drugs&#xD;
&#xD;
          -  Screening test AST, ALT &gt; ULN x 1.5 Creatinine clearance &lt; 60mL/min/1.73m2 QTcB&#xD;
             interval &gt; 450 ms Serologic test positive(Hepatitis B, Hepatitis C, HIV)&#xD;
&#xD;
          -  SBP &lt;90 mmHg or &gt;150 mmHg, DBP &lt;60 mmHg or &gt; 100 mmHg&#xD;
&#xD;
          -  Drub abuse history&#xD;
&#xD;
          -  Administration of any OTC drug, Herbal drug, Investigational medication within 2weeks&#xD;
&#xD;
          -  Participation in other clinical trial within 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SeungHwan Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soojin Jun</last_name>
    <phone>8228879971</phone>
    <email>sjjun@sparkbio.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>YongMi Yu</last_name>
    <phone>8228879905</phone>
    <email>ymyu@sparkbio.co.kr</email>
  </overall_contact_backup>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>February 27, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>April 2, 2023</last_update_submitted>
  <last_update_submitted_qc>April 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HMGB1</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

